Navigation Links
Trending HealthEconomics.Com Pharma Pricing, Reimbursement, and Health Policy Stories Feature Rising Trend in Pharma Price Cuts to Secure Reimbursement
Date:12/14/2012

Ponte Vedra Beach, FL (PRWEB) December 13, 2012

The most-read story on HealthEconomics.Com HealthCare Value and Market Access News this week examines the growing trend of pharmaceutical companies to drop prices by up to one-half to convince the National Institute for Health and Clinical Excellence (NICE) that the drugs are cost-effective. According to NICE Chairman Michael Rawlins, these “commercially confidential” price cuts are becoming both more common and larger, approaching 50% discounts. This poses implications for international reference pricing which examines drug prices in other countries in order to set a reimbursable price with the intent to contain growth in pharmaceutical expenditures. This story and another describing the discount offered by Bristol-Myers Squibb Co. on their drug for rheumatoid arthritis reversing a rejection in 2011 are covered more in-depth on HealthEconomics.Com.

Another top story on HealthEconomics.Com explored the response by major employers in the United States to deny health insurance to newly hired employees who work fewer than 30 hours per week, starting in January 2013. Many health care policy experts believe this shift by the nation’s largest employer to be an attempt to shift costs of paying for its employees’ health insurance to place the burden on the federal government, with the implementation of the Affordable Care Act. This story is featured on HealthEconomics.Com News on Health Policy.

In a story on unintended consequences associated with health reform, Quebec
'/>"/>

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Page: 1 2

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
2. WuXi PharmaTech Announces Third-Quarter 2011 Results
3. Pharmasset to Present at the Lazard Capital Markets Healthcare Conference
4. Pharmasset Reports Fiscal Year End 2011 Financial Results
5. Internal and External Communications Excellence for the Pharmaceutical Industry: Increasing Organizational Effectiveness
6. Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944
7. PRA Expert to Present at Pharmacovigilance Conference
8. Nutra Pharma Announces Publication of a New Mechanism Study of Alpha-Cobratoxin in the Treatment of Pain
9. InnoPharma Completes $15 Million Series A Financing
10. TetraLogic Pharmaceuticals Announces Initiation of a Phase 1/2 Clinical Trial of TL32711 in Patients with Acute Myelogenous Leukemia (AML)
11. ViroPharma to Participate in Two December Healthcare Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)... (PRWEB) October 24, 2014 The ... the nation’s leading nonprofit authority on the use ... information exchange, announces its appointment of four new ... The workgroup leaders include:, ,     Peter ...     Erik Pupo, Specialist Leader, Deloitte Consulting LLP ...
(Date:10/25/2014)... NC (PRWEB) October 24, 2014 A ... to overcome several pitfalls of current skin grafting technologies, ... and produces hair. The method, outlined in the October ... breakthrough for treating deep skin injuries that result from ... injury completely destroys the skin’s regenerative elements. These wounds ...
(Date:10/25/2014)... 2014  RegeneRx Biopharmaceuticals, Inc. (OTCBB: RGRX) ("the Company" ... Fourth International Symposium on Thymosins in Health and Disease ... "When thymosin beta 4 (TB4) linked with rhodamine ... cavity in a rodent model of stroke, it was ... parenchyma (the functional tissue of the brain).   The leakage ...
(Date:10/22/2014)... New test innovations will be the source ... test industry, especially as companies struggle with reimbursement challenges, ... than 25 testing innovations in important disease areas in ... products. Kalorama details the new approaches its biennial survey of ... Vitro Diagnostic Tests , 9th Edition . ...
Breaking Biology Technology:WEDI Appoints Four New Security and Privacy Workgroup Co-chairs 2New engineering method shows promise for faster healing, more cosmetically appealing skin grafts 2New engineering method shows promise for faster healing, more cosmetically appealing skin grafts 3Researchers Report Thymosin Beta 4 Crosses Blood-Brain Barrier In Animal Stroke Model 2Report: Radical New IVD Test Approaches Key To Growth 2Report: Radical New IVD Test Approaches Key To Growth 3
... YM BioSciences Inc. (NYSE Amex: YMI ; TSX: ... patients enrolled in the Phase I/II trial for its JAK1/JAK2 ... an oral presentation at the 52nd American Society of Hematology ... "Anemia is the most serious symptom associated with myelofibrosis, so ...
... Viruses have a bad rep—and rightly so. The ... itself makes it a destructive scourge to animals and ... the University of Maryland,s A. James Clark School of ... together by Professor Reza Ghodssi, is turning the tables, ...
... YORK, Dec. 6, 2010 See video from ... Novartis announced 24-month data showing that ... the treatment of adult patients with newly diagnosed ... chronic phase1. These new data, from the first ...
Cached Biology Technology:YM BioSciences Reports Positive Interim Data Including Substantial Anemia Response from Phase I/II Trial of JAK1/JaK2 Inhibitor CYT387 2YM BioSciences Reports Positive Interim Data Including Substantial Anemia Response from Phase I/II Trial of JAK1/JaK2 Inhibitor CYT387 3YM BioSciences Reports Positive Interim Data Including Substantial Anemia Response from Phase I/II Trial of JAK1/JaK2 Inhibitor CYT387 4YM BioSciences Reports Positive Interim Data Including Substantial Anemia Response from Phase I/II Trial of JAK1/JaK2 Inhibitor CYT387 5YM BioSciences Reports Positive Interim Data Including Substantial Anemia Response from Phase I/II Trial of JAK1/JaK2 Inhibitor CYT387 6Bad Virus Put to Good Use: Breakthrough Batteries 2Bad Virus Put to Good Use: Breakthrough Batteries 3Bad Virus Put to Good Use: Breakthrough Batteries 4Bad Virus Put to Good Use: Breakthrough Batteries 5Bad Virus Put to Good Use: Breakthrough Batteries 6
(Date:10/25/2014)... 2014 This report covers the specifics of ... in heavy pursuit of research due to its versatility ... to other RNA components. miRNA,s non-coding nature and ability ... for use as a biomarker for a variety of ... diagnostics for the advancement in therapeutic development. Furthermore there ...
(Date:10/25/2014)... , Oct. 23, 2014 Research ... "Biometrics Market in Europe 2014-2018" report to their ... helps to assess individuals on the basis of their ... identification of both physiological traits such as fingerprints, face ... and behavioral traits such as keystroke patterns and speech ...
(Date:10/22/2014)... , Oct. 20, 2014 The Nano-Bio ... States Air Force Research Laboratory (AFRL), has chosen a ... (AzCIM) at the University of Arizona College of Medicine ... funding.  The AzCIM project,s goal is to assess different ... collect different volumes of sweat under a variety of ...
Breaking Biology News(10 mins):MicroRNA: An Insight to miRNA-based microarrays, diagnostics and therapeutics Overview, Cambridge Healthtech Advisors 2Biometrics Market in Europe 2014-2018: Key Vendors are 3M Cogent, Cognitec, NEC and Safran 2Biometrics Market in Europe 2014-2018: Key Vendors are 3M Cogent, Cognitec, NEC and Safran 3Nano-Bio Manufacturing Consortium Selects Project Proposed by Arizona Center for Integrative Medicine to Optimize Human Performance Monitoring Techniques 2Nano-Bio Manufacturing Consortium Selects Project Proposed by Arizona Center for Integrative Medicine to Optimize Human Performance Monitoring Techniques 3
... fossil discovered in Tunisia represents the oldest known ancestor of ... mammals. The find is described in research published January 16 ... Julien Benoit and colleagues from the University of Science and ... cow ancestors have been found in Jamaica, but the Tunisian ...
... are facing a troubling consequence of their own success. They ... life expectancy. However, those same drugs will eventually cause the ... current treatments. With a new $3.4 million grant from ... leading a team of researchers who want to stay a ...
... launch pad or even in orbit. They start years before ... to expand our view and understanding of the planet. NASA ... for the Aerosol-Cloud-Ecosystem (ACE) mission, a satellite that "will dramatically ... clouds and aerosols," said ACE science lead David Starr of ...
Cached Biology News:Researchers attack HIV's final defenses before drug-resistant mutations emerge 2Researchers attack HIV's final defenses before drug-resistant mutations emerge 3PODEX experiment to reshape future of atmospheric science 2PODEX experiment to reshape future of atmospheric science 3PODEX experiment to reshape future of atmospheric science 4PODEX experiment to reshape future of atmospheric science 5
... (EMSA) is a powerful tool for evaluating ... shift or gel retardation, the assay is ... to electrophoresis, free DNA will migrate differently ... Chemiluminescent EMSA Kit is a nonradioactive system ...
... The Cell Lab Quantas unique combination ... unsurpassed population resolution capabilities and accurate ... multiple excitation wavelengths, including UV, allowing ... of multi-color applications typically only achievable ...
... novel procedure for the uniform amplification and ... DNA from small samples. This method has ... highly reproducible amplification and labeling procedure for ... Mini Kit module (QIAGEN) and a ULS ...
... using PULSin may be superior to transfection ... traditional transfection, with PULSin you can study ... time course of proteins in cells. Likewise, ... information than traditional RNA interference experiments. ...
Biology Products: